Latest News and Press Releases

Replimune allegedly overstated the IGNYTE trial’s prospects despite major issues that led the FDA to deem it inadequate and not well-controlled.

Replimune allegedly overstated its IGNYTE trial despite flaws later flagged by the FDA, leaving investors misled and damaged when the truth emerged.

Allegedly, defendants overstated IGNYTE trial prospects despite issues that led the FDA to deem it inadequate, misleading investors and causing losses.

Replimune allegedly overstated IGNYTE trial prospects; FDA deemed it inadequate, and investors suffered damages when the truth emerged.

The lawsuit alleges Replimune overstated IGNYTE prospects; FDA deemed the trial inadequate, making prior statements false and harming investors.

The lawsuit alleges Replimune overstated the IGNYTE trial’s prospects despite known issues, leading the FDA to deem it inadequate and investors harmed.

Lawsuit alleges Replimune overstated IGNYTE trial prospects despite flaws; FDA deemed trial inadequate, causing investor losses.

The Complaint claims Replimune overstated IGNYTE’s prospects despite flaws later cited by the FDA; after a CRL rejection, shares fell 77% on July 22, 2025.

NEW YORK, Aug. 30, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...

NEW YORK, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...